Literature DB >> 26747094

The purine analogues abacavir and didanosine increase acetaminophen-induced hepatotoxicity by enhancing mitochondrial dysfunction.

Ana Blas-García1, Alberto Martí-Rodrigo2, Víctor M Víctor3, Miriam Polo4, Fernando Alegre4, Haryes A Funes2, Nadezda Apostolova5, Juan V Esplugues6.   

Abstract

BACKGROUND: NRTIs are essential components of HIV therapy with well-documented, long-term mitochondrial toxicity in hepatic cells, but whose acute effects on mitochondria are unclear. As acetaminophen-induced hepatotoxicity also involves mitochondrial interference, we hypothesized that it would be exacerbated in the context of ART.
METHODS: We evaluated the acute effects of clinically relevant concentrations of the most widely used NRTIs, alone or combined with acetaminophen, on mitochondrial function and cellular viability.
RESULTS: The purine analogues abacavir and didanosine produced an immediate and concentration-dependent inhibition of oxygen consumption and complex I and III activity. This inhibition was accompanied by an undermining of mitochondrial function, with increased production of reactive oxygen species and reduction of mitochondrial membrane potential and intracellular ATP levels. However, this interference did not compromise cell survival. Co-administration with concentrations of acetaminophen below those considered hepatotoxic exacerbated the deleterious effects of both compounds on mitochondrial function and compromised cellular viability, showing a clear correlation with diminished glutathione levels.
CONCLUSIONS: The simultaneous presence of purine analogues and low concentrations of acetaminophen significantly potentiates mitochondrial dysfunction, increasing the risk of liver injury. This new mechanism is relevant given the liver's susceptibility to mitochondrial dysfunction-related toxicity and the tendency of the HIV infection to increase oxidative stress.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26747094     DOI: 10.1093/jac/dkv424

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.

Authors:  Giordano Madeddu; Stefano Rusconi; Alessandro Cozzi-Lepri; Simona Di Giambenedetto; Stefano Bonora; Alessia Carbone; Andrea De Luca; Nicola Gianotti; Antonio Di Biagio; Andrea Antinori
Journal:  Infection       Date:  2017-05-05       Impact factor: 3.553

2.  Central nervous system-penetrating antiretrovirals impair energetic reserve in striatal nerve terminals.

Authors:  Kelly L Stauch; Katy Emanuel; Benjamin G Lamberty; Brenda Morsey; Howard S Fox
Journal:  J Neurovirol       Date:  2017-09-11       Impact factor: 2.643

3.  Hepatic effect of sofosbuvir and daclatasvir in thioacetamide-induced liver injury in rats.

Authors:  Mohamed A Ibrahim; Asmaa Abdel-Aziz; Azza El-Sheikh; Maha Kamel; Al-Zahraa Khalil; Hisham Abdelhaleem
Journal:  Clin Exp Hepatol       Date:  2018-09-10

4.  Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.

Authors:  Joseph W George; Jane E Mattingly; Nashanthea J Roland; Cassandra M Small; Benjamin G Lamberty; Howard S Fox; Kelly L Stauch
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

Review 5.  Abacavir-induced liver toxicity.

Authors:  Maria Diletta Pezzani; Chiara Resnati; Valentina Di Cristo; Agostino Riva; Cristina Gervasoni
Journal:  Braz J Infect Dis       Date:  2016-04-04       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.